{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:23:06Z","timestamp":1787678586300,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["21K06707"],"award-info":[{"award-number":["21K06707"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>An inexpensive, simple, and accurate plasma concentration measurement system is needed to actively conduct pharmacokinetic and pharmacodynamic analyses of vadadustat, hypoxia-inducible factor-prolyl hydroxylase inhibitor, in clinical settings. In this study, the authors aimed to develop a method for measuring vadadustat in human plasma that could be applied for therapeutic drug monitoring using high-performance liquid chromatography with ultraviolet detection (HPLC-UV) in a clinical setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Plasma samples (100 \u03bcL) were pretreated with acetonitrile using butyl paraoxybenzoate as an internal standard. Chromatographic separation was performed on a SunShell PFP C18 column (2.6 \u03bcm, 4.6 mm \u00d7 150 mm). The mobile phase consisted of (A) 20 mM of phosphate buffer (pH 2.4) and (B) acetonitrile (60:40, v\/v), delivered isocratically at a flow rate of 1 mL\/min. The analytes were detected by UV absorbance at a wavelength of 220 nm, and the column temperature was 40\u00b0C. To evaluate the applicability of HPLC-UV in a clinical setting, blood samples were collected at 19 time points from 7 patients who had been taking vadadustat.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The calibration curve was linear over the concentration range of 0.2\u2013150 mcg\/mL (<jats:italic toggle=\"yes\">R<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup> &gt; 0.99). Intra-assay and interassay accuracy, precision, and stability met the Food and Drug Administration recommendations. The vadadustat plasma concentrations of patients analyzed using the current HPLC-UV method were almost equal to those measured using ultra-performance liquid chromatography-tandem mass spectrometry (mean difference: 0.13 mcg\/mL). Large variability in the dose-adjusted plasma concentrations of vadadustat at 12 hours after administration was observed between patients (coefficient of variation = 57.6%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This HPLC-UV method is a simple, accurate quantification method for evaluating plasma concentrations in patients taking vadadustat in a clinical setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001238","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T15:40:00Z","timestamp":1719934800000},"page":"813-819","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Quantification of the Plasma Concentration of Vadadustat by High-Performance Liquid Chromatography with Ultraviolet Detection and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-6287","authenticated-orcid":false,"given":"Satoshi","family":"Yokoyama","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hirosaki University Hospital, Hirosaki, Aomori, Japan;"},{"name":"Department of Pharmaceutical Science, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hirosaki University Hospital, Hirosaki, Aomori, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Shimada","sequence":"additional","affiliation":[{"name":"Community Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hirosaki University Hospital, Hirosaki, Aomori, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ishiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hirosaki University Hospital, Hirosaki, Aomori, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Nursing Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-6423","authenticated-orcid":false,"given":"Takenori","family":"Niioka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hirosaki University Hospital, Hirosaki, Aomori, Japan;"},{"name":"Department of Pharmaceutical Science, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv Ther"},{"key":"R2-20250603","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transpl"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1159\/000528443","article-title":"Overall adverse event profile of vadadustat versus darbepoetin alfa for the treatment of anemia associated with chronic kidney disease in phase 3 trials","volume":"53","author":"Agarwal","year":"2022","journal-title":"Am J Nephrol"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/ndt\/gfaa060","article-title":"Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized phase 2 trials in Japanese patients","volume":"36","author":"Nangaku","year":"2020","journal-title":"Nephrol Dial Transpl"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1681\/ASN.2020091311","article-title":"Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD","volume":"32","author":"Nangaku","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11255-022-03316-z","article-title":"Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis","volume":"55","author":"Huang","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1124\/jpet.122.001126","article-title":"Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia","volume":"383","author":"Zuk","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cpdd.927","article-title":"Effect of moderate hepatic impairment on the pharmacokinetics of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor","volume":"10","author":"Chavan","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/hep.1840130428","article-title":"Is glucuronidation truly preserved in patients with liver disease?","volume":"13","author":"Hoyumpa","year":"1991","journal-title":"Hepatology"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-inducible factor activators in renal anemia: current clinical experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/cpdd.1033","article-title":"Effect of phosphate binders and a dietary iron supplement on the pharmacokinetics of a single dose of vadadustat in healthy adults","volume":"11","author":"Paulson","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.clinthera.2021.06.013","article-title":"In vitro and clinical pharmacokinetic studies of the effects of iron-containing agents on vadadustat, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor","volume":"43","author":"Kokado","year":"2021","journal-title":"Clin Ther"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.aca.2009.10.004","article-title":"A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation","volume":"656","author":"Nov\u00e1kov\u00e1","year":"2009","journal-title":"Anal Chim Acta"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.ki.5002017","article-title":"Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study","volume":"71","author":"Yamagata","year":"2007","journal-title":"Kidney Int"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.crphar.2021.100020","article-title":"Drug-drug interactions in polypharmacy patients: the impact of renal impairment","volume":"2","author":"Papotti","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:16:13Z","timestamp":1748970973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001238","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,2]]},"assertion":[{"value":"2023-09-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}